The annual Eastern Canadian Colorectal Cancer Consensus Conference held in Montreal, Quebec, 17-19 October 2013, marked the 10-year anniversary of this meeting that is attended by leaders in medical, radiation, and surgical oncology. The goal of the attendees is to improve the care of patients affected by gastrointestinal malignancies. Topics discussed during the conference included pancreatic cancer, rectal cancer, and metastatic colorectal cancer.

The annual Eastern Canadian Colorectal Cancer Consensus Conference was held in Halifax, Nova Scotia, October 20-22, 2011. Health care professionals involved in the care of patients with colorectal cancer participated in presentation and discussion sessions for the purposes of developing the recommendations presented here. This consensus statement addresses current issues in the management of rectal cancer, including pathology reporting, neoadjuvant systemic and radiation therapy, surgical techniques, and palliative care of rectal cancer patients. Other topics discussed include multidisciplinary cancer conferences, treatment of gastrointestinal stromal tumours and pancreatic neuroendocrine tumours, the use of folfirinox in pancreatic cancer, and treatment of stage II colon cancer.

e14686 Background: There is significant controversy surrounding the management of surgically resectable MRC. The use and timing of neoadjuvant chemotherapy, pelvic radiation, and relative risks and benefits of a combined surgical resection are areas of debate among surgeons, medical, and radiation oncologists. The TOHCC multidisciplinary Cancer Conferences (MCC) provide an opportunity to discuss these cases and propose treatment plans for these patients. Methods: We conducted a retrospective chart review of all the cases of MRC which were discussed at MCC at the TOHCC from November 2007 until October 2009. Information collected included patient demographics, site of metastases, the treatment they received prior to their case being discussed at MCC (past surgeries, chemotherapy, radiotherapy), the treatment plan discussed at MCC, treatment actually administered post MCC discussion, and patient outcome at 6 months. Results: Forty-two patients with MRC were reviewed. The most common sites of metastases were liver (45.2%) and lung (31%). Once diagnosed with metastatic disease, prior to the MCC, patients had received the following treatments alone or in combination: chemotherapy (33.3%), radiotherapy (21.4%), surgery (19.0%), no treatment (n=57.1%). After their case was presented, 38 patients (90.5%) received the treatment recommended at the MCC , while 4 (9.5%) did not. Treatment post MCC included: chemotherapy (neoadjuvant: 38.1%; adjuvant: 23.8%; palliative: 28.6%), radiotherapy (neoadjuvant: 14.3%; adjuvant: 7.1%; palliative: 7.1%) and surgery (31.0%). Conclusions: There is no standardized approach to the management of MRC. Given its complexity, many cases are reviewed at MCC, which allow coordination for multidisciplinary care of these patients. The results of this study suggest that in a majority of cases, the recommendations brought forth at MCC are indeed acted upon. Given that these meetings have a significant impact on the treatment plan and outcome of patients with MRC, they should represent the standard of care when treating this disease.

The annual Eastern Canadian Colorectal Cancer Consensus Conference was held in Ottawa, Ontario, October 22-23, 2010. Health care professionals involved in the care of patients with colorectal cancer participated in presentation and discussion sessions for the purpose of developing the recommendations presented here. This consensus statement addresses current issues in the management of colorectal cancer, such as the use of epidermal growth factor inhibitors in metastatic colon cancer, the benefit of calcium and magnesium with oxaliplatin chemotherapy, the role of microsatellites in treatment decisions for stage II colon cancer, the staging and treatment of rectal cancer, and the management of colorectal and metastatic pancreatic cancers.

e14631 Background: NETs are usually diagnosed and followed via a variety of imaging modalities, including MRI, CT scans and somatostatin scintigraphy (OctreoScan, SRS). SRS works by detecting somatostatin receptors found on NETs. There is ongoing debate as to which imaging modality should routinely be used to diagnose and follow patients affected with NETs. This project aims to determine if the information gathered from SRS corresponds or adds to results obtained from modern CT or MRI. METHODS We conducted a retrospective chart review by identifying all patients diagnosed with a NET who were seen at TOHCC between 2003-01-01 and 2009-03-31. We then identified all patients who underwent an SRS within 30 days of a CT or MRI. Results of the SRS were then compared against those of the latter imaging modalities. RESULTS 70 patients with a diagnosis of NET were identified. Of these, 28 had an SRS within 30 days of a CT or MRI. 5 patients had serial SRS plus either a CT or MRI within the defined time window. In total, 33 SRS results were allowed in the study. When compared to the results of the CT or MRI, 13 (39.4%) were true negatives (TN) SRS, 9 (33.3%) were true positives (TP), and 8 (24.3%) were false negatives (FN) in the setting of metastatic disease. The liver was the most common site missed. One patient had a false positive (FP) SRS (3.0%) with the location of the supposed lesion thought to be in the small bowel. CONCLUSIONS The sensitivity of CT scans and MRIs is superior to that of SRS when investigating NET. There were no cases were an SRS identified lesions that were truly present but not seen on CT or MRI. The most common site missed by the SRS was the liver. This data suggest that SRS does not provide additional information and does not appear to be useful in the diagnosis and follow up of patients with NET, however, further research is needed.